ONCY
Oncolytics Biotech, Inc. Common Shares
stockNASDAQ
oncolytics biotech is a biotechnology company focused on the development of oncolytic viruses as potential therapeutics for use in a broad range of cancers. the company is conducting clinical studies using reolysin®, its proprietary formulation of the human reovirus, in some of the most prevalent forms of the disease including lung, colorectal and pancreatic cancers. oncolytics' clinical program includes a number of human trials at a variety of stages including a phase iii trial in head and neck cancers. the company has advanced its product manufacturing and intellectual property initiatives in parallel with its clinical development program to support development of a commercial product.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.66 | 2026-09-28 | -5.43% | -2.370 |
| 1M | 0.84 | 2026-09-04 | -25.64% | 0.506 |
| 3M | 0.88 | 2026-07-06 | -28.77% | 1.339 |
| 6M | 0.95 | 2026-04-06 | -34.00% | 1.440 |
| 1Y | 1.38 | 2025-10-03 | -54.56% | 1.599 |
| 2Y | 1.10 | 2024-10-04 | -43.00% | — |
| 5Y | 1.89 | 2021-10-04 | -66.83% | 0.949 |
Oncolytics Biotech, Inc. Common Shares (NASDAQ:ONCY) stock price today is $0.63, and today's volume is 611,814. ONCY is down 2.215% today. The 30 day average volume is 966,941. ONCY market cap is $79.95M with 127.51M shares outstanding.